Versant Vantage II, L.P.'s Net Worth

$111 Million

Who is Versant Vantage II, L.P.?

Versant Vantage II, L.P. has an estimated net worth of $111 Million. This is based on reported shares across multiple companies, which include Turnstone Biologics Corp., Graphite Bio, Inc., Century Therapeutics, Inc., and Tempest Therapeutics, Inc..

SEC CIK

Versant Vantage II, L.P.'s CIK is 0001832235

Past Insider Trading and Trends

2023 was Versant Vantage II, L.P.'s most active year for acquiring shares with 9 total transactions. Versant Vantage II, L.P.'s most active month to acquire stocks was the month of June. 2023 was Versant Vantage II, L.P.'s most active year for disposing of shares, totalling 17 transactions. Versant Vantage II, L.P.'s most active month to dispose stocks was the month of June. 2021 saw Versant Vantage II, L.P. paying a total of $5,060,000.00 for 24,701,552 shares, this is the most they've acquired in one year. In 2022 Versant Vantage II, L.P. cashed out on 1,093,796 shares for a total of $7,166,610.00, their largest year based on trade value.